Compare Vital Farms Inc (VITL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vital Farms Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Vital Farms Inc trades at $9.81 (market cap $424.16M), while State Street SPDR S&P Biotech ETF trades at $159.85. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals.
| VITL | XBI | |
|---|---|---|
Market Cap | $424.16M | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $48.56 | $169.55 |
52-Week Low | $8.28 | $93.43 |
Enterprise Value | $511.17M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vital Farms (VITL) trades at $10.08, up 1.61% on the day, but faces bearish technical signals with key support at $9. The company reported a challenging Q2 2026 with a net loss per share of $0.47, though revenue of $166 million slightly beat expectations. Gross margin collapsed to 6.6% amid industry oversupply, but management reaffirmed full-year guidance and secured a $125 million term loan for stability.
The outlook is cautious; analyst consensus is a Buy with a $13.00 price target, but near-term risks include persistent margin pressure, cash burn, and competitive pricing gaps. Long-term recovery depends on execution against guidance and market stabilization.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
